title: Lenalidomide-Associated ITP.
abstract: Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
authors.affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
authors.forename: Christina I
authors.initials: CI
authors.lastname: Herold
authors.forename: Cristina
authors.initials: C
authors.lastname: Gasparetto
authors.forename: Gowthami M
authors.initials: GM
authors.lastname: Arepally